Combinational Therapy in Triple Negative Breast Cancer
- 1st Edition - May 5, 2022
- Author: Manzoor Ahmad Mir
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 6 1 3 6 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 6 1 3 7 - 0
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various p… Read more
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options.
The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer.
- Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options
- Discusses novel targets and pathways involved in TNBC
- Provides insights and approaches for future research on TNBC
Researchers and graduate students on cancer research
Oncologists, medical doctors
1. TNBC: an aggressive subtype of breast cancer2. Novel Biomarkers and Genetics: Role and Perspective3. Current Therapeutics and Treatment: Significance and controversies4. Conventional Adjuvant Chemotherapy in combination with Surgery, Radiotherapy and other non-specific agents5. Role of Immune system in Oncometastasis: A New Perspective6. What if immunotherapy is used in combination with the chemotherapy?7. Will there be any improvement if chemotherapy is combined with target specific biological agents?8. Different drug delivery Approaches in combinational Therapy
- Edition: 1
- Published: May 5, 2022
- Language: English
MM
Manzoor Ahmad Mir
Dr. Manzoor Ahmad Mir holds a Master's in Zoology from HNBG Central University and completed his Ph.D. in Immunology at Jawaharlal Nehru University, New Delhi, and CSIR-Institute of Microbial Technology, Chandigarh. His research focuses on cancer biology, combination therapy in breast cancer, and tuberculosis immunology. Dr. Mir has published over 50 high-impact research papers and book chapters. He has authored more than 15 books with international publishers of repute. He serves on the editorial boards of prestigious journals. He is a member of several scientific organizations, including the American Association of Cancer Research and the Royal British Society. He has received the TARE Fellowship and the SRFP-2019 from the Indian Science Academies. Dr. Mir teaches Cancer Biology and Immunology at the University of Kashmir, where he heads the Department of Bioresources.
Affiliations and expertise
Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, IndiaRead Combinational Therapy in Triple Negative Breast Cancer on ScienceDirect